RenovoRx (RNXT) Competitors $1.35 +0.05 (+3.85%) Closing price 07/3/2025 03:41 PM EasternExtended Trading$1.35 0.00 (0.00%) As of 07/3/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNXT vs. FDMT, LRMR, TLSA, ENGN, DRUG, OGI, CTMX, PBYI, VYGR, and ALMSShould you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include 4D Molecular Therapeutics (FDMT), Larimar Therapeutics (LRMR), Tiziana Life Sciences (TLSA), enGene (ENGN), Bright Minds Biosciences (DRUG), Organigram Global (OGI), CytomX Therapeutics (CTMX), Puma Biotechnology (PBYI), Voyager Therapeutics (VYGR), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. RenovoRx vs. Its Competitors 4D Molecular Therapeutics Larimar Therapeutics Tiziana Life Sciences enGene Bright Minds Biosciences Organigram Global CytomX Therapeutics Puma Biotechnology Voyager Therapeutics Alumis RenovoRx (NASDAQ:RNXT) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends. Which has more volatility & risk, RNXT or FDMT? RenovoRx has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.81, suggesting that its share price is 181% more volatile than the S&P 500. Do analysts rate RNXT or FDMT? RenovoRx presently has a consensus price target of $7.25, suggesting a potential upside of 437.04%. 4D Molecular Therapeutics has a consensus price target of $29.56, suggesting a potential upside of 621.75%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than RenovoRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.004D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is RNXT or FDMT more profitable? RenovoRx has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. 4D Molecular Therapeutics' return on equity of -33.26% beat RenovoRx's return on equity.Company Net Margins Return on Equity Return on Assets RenovoRxN/A -119.58% -88.01% 4D Molecular Therapeutics -767,126.06%-33.26%-30.68% Which has stronger valuation & earnings, RNXT or FDMT? RenovoRx is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovoRx$40K1,234.24-$8.81M-$0.40-3.384D Molecular Therapeutics$40K4,743.03-$160.87M-$3.18-1.29 Do institutionals & insiders hold more shares of RNXT or FDMT? 3.1% of RenovoRx shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 9.1% of RenovoRx shares are held by insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer RNXT or FDMT? In the previous week, 4D Molecular Therapeutics had 8 more articles in the media than RenovoRx. MarketBeat recorded 8 mentions for 4D Molecular Therapeutics and 0 mentions for RenovoRx. 4D Molecular Therapeutics' average media sentiment score of 0.11 beat RenovoRx's score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment RenovoRx Neutral 4D Molecular Therapeutics Neutral Summary4D Molecular Therapeutics beats RenovoRx on 11 of the 15 factors compared between the two stocks. Get RenovoRx News Delivered to You Automatically Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNXT vs. The Competition Export to ExcelMetricRenovoRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.74M$2.90B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-3.3821.5627.5820.25Price / Sales1,234.24281.07417.23118.60Price / CashN/A42.7336.8958.07Price / Book7.117.518.035.67Net Income-$8.81M-$55.05M$3.18B$249.21M7 Day Performance5.47%4.61%2.91%3.28%1 Month Performance-3.57%4.72%3.72%5.56%1 Year Performance18.42%5.92%36.04%21.13% RenovoRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNXTRenovoRx2.8872 of 5 stars$1.35+3.8%$7.25+437.0%+20.5%$49.74M$40K-3.386Gap DownFDMT4D Molecular Therapeutics2.3099 of 5 stars$4.04+8.9%$29.56+631.6%-80.4%$186.94M$40K-1.27120News CoverageAnalyst ForecastLRMRLarimar Therapeutics1.6002 of 5 stars$2.91+0.5%$18.50+536.8%-58.8%$186.90MN/A-1.9630Gap DownTLSATiziana Life Sciences0.6872 of 5 stars$1.58-0.1%N/A+86.7%$184.04MN/A0.008ENGNenGene2.6403 of 5 stars$3.57-1.9%$23.29+552.3%-56.8%$183.21MN/A-2.1731DRUGBright Minds Biosciences2.9217 of 5 stars$25.67-1.7%$83.25+224.4%+2,544.9%$180.58MN/A-71.25N/ANews CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap UpOGIOrganigram Global0.6587 of 5 stars$1.35flatN/A-10.7%$180.15M$194.09M13.45860News CoverageCTMXCytomX Therapeutics4.0662 of 5 stars$2.22-2.4%$5.33+140.8%+91.5%$177.93M$138.10M4.60170PBYIPuma Biotechnology4.1894 of 5 stars$3.60+4.8%$7.00+94.7%+17.5%$177.92M$230.50M4.66200VYGRVoyager Therapeutics3.5728 of 5 stars$3.16+1.4%$13.39+324.4%-57.6%$174.60M$80M-2.16100ALMSAlumis3.0979 of 5 stars$3.14+4.5%$22.86+629.1%N/A$170.85MN/A0.00N/A Related Companies and Tools Related Companies FDMT Alternatives LRMR Alternatives TLSA Alternatives ENGN Alternatives DRUG Alternatives OGI Alternatives CTMX Alternatives PBYI Alternatives VYGR Alternatives ALMS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNXT) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
